This study will assess the efficacy and safety of intravenous beta-lactam, in comparison with ceftriaxone, in hospitalized patients with community-acquired pneumonia not caused by Legionella. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.

Inclusion Criteria:

• male or female patients at least 18 years of age;
• hospitalization with community-acquired pneumonia or development of pneumonia within 48 hours of being hospitalized for another reason;
• fever;
• new or increased productive cough;
• chest pain, shortness of breath, or rapid breathing.

Exclusion Criteria:

• requiring intubation or ventilation;
• nursing home or extended care within 60 days before study;
• concomitant bacterial infection requiring antibiotics;
• long-term immunosuppressive therapy.